复发性恶性胶质瘤质子再程放疗的前瞻性登记研究临床结局
基于前瞻性质子协作组登记数据库,纳入143例接受质子再程放疗的复发性恶性胶质瘤患者,中位随访11.2个月。中位无进展生存期8.1个月,中位总生存期11.2个月;多因素分析中仅少突胶质细胞瘤和距前次放疗间隔>60个月与总生存改善相关。急性与晚期3级毒性分别为7%和4%,放射性坏死发生率为19%。
要点
- 质子再程放疗耐受性良好,急性与晚期3级毒性分别为7%和4%。
- 多因素分析中少突胶质细胞瘤和放疗间隔>60个月与总生存改善独立相关。
- 放射性坏死发生率为19%,中位再程放疗剂量44.6 Gy。
核心结论
- 质子再程放疗在复发性恶性胶质瘤中耐受性良好,结局因临床预后因素而异。
- 毒性率与光子放疗文献相似,尽管中位再程放疗处方剂量较高。
研究设计与样本
- 仅纳入至少有一次随访记录者,共143例,中位随访11.2个月。
主要发现
- 中位无进展生存期8.1个月,中位总生存期11.2个月。
- 单因素分析中,少突胶质细胞瘤和星形细胞瘤组织学、间隔>60个月、ECOG体能状态0、再程放疗剂量≥50 Gy与总生存改善相关。
- 多因素分析中,仅少突胶质细胞瘤和间隔>60个月与总生存改善独立相关。
- 急性3级毒性发生率为7%,晚期3级毒性发生率为4%,急性3级毒性与体能状态差相关。
- 放射性坏死发生率为19%。
关键数值与推荐
- 前次放疗中位剂量58.5 Gy(IQR 54-60 Gy),再程放疗中位剂量44.6 Gy(IQR 39.4-55.9 Gy)。
- 前次放疗至再程放疗的中位间隔为42.4个月。
临床怎么用
- 质子再程放疗可作为复发性恶性胶质瘤的选择,需结合组织学类型和距前次放疗间隔评估获益。
- 体能状态差者急性3级毒性风险较高,应加强评估与监测。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Optimal treatment for recurrent glioma after prior radiation therapy (RT) is not well established. Proton therapy (PT) is increasingly used for reirradiation (ReRT); however, treatment outcomes, toxicities, and prognostic factors for PT-ReRT remain poorly defined. METHODS AND MATERIALS: The prospective, multi-institutional Proton Collaborative Group registry was queried for patients with malignant glioma who underwent PT-ReRT between July 2011 and December 2023; only patients with at least one follow-up encounter were included. Overall survival (OS) and progression-free survival were assessed using the Kaplan-Meier method, and Cox proportional hazards regression was used for uni- and multivariable analyses (univariable analysis and multivariable analysis). RESULTS: The study cohort included 143 patients, the median follow-up was 11.2 months, and the median time interval (TI) from prior RT (median 58.5 Gy, IQR, 54-60 Gy) to PT-ReRT (median 44.6 Gy, IQR, 39.4-55.9 Gy) was 42.4 months. Median progression-free survival and OS were 8.1 and 11.2 months, respectively. On univariable analysis, improved OS was associated with oligodendroglioma and astrocytoma histology compared to glioblastoma, TI >60 months, Eastern Cooperative Oncology Group performance status 0, and ReRT dose ≥50 Gy. On multivariable analysis, improved OS remained associated only with oligodendroglioma and TI >60 months. Acute and late grade 3 toxicity occurred in 7% and 4%, respectively. Acute grade 3 toxicity was associated with poor performance status. Incidence of radiographic radiation necrosis was 19%. CONCLUSIONS: In the largest series of glioma PT-ReRT reported to date, retreatment was well tolerated with variable outcomes based on clinical prognostic factors. Toxicity rates were similar compared to photon-based literature despite a high median ReRT prescription dose.
引用
- Gal O, Mihalcik S, Halasz LM, et al. Clinical Outcomes After Proton Therapy Reirradiation for Recurrent Malignant Glioma: Analysis From the Prospective Proton Collaborative Group Registry. Adv Radiat Oncol. 2025. PMID: 40686741. doi:10.1016/j.adro.2025.101834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。